CASI Pharmaceuticals (NASDAQ:CASI) Releases Quarterly Earnings Results

CASI Pharmaceuticals (NASDAQ:CASI) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.79) earnings per share for the quarter, Zacks reports. CASI Pharmaceuticals had a negative net margin of 143.18% and a negative return on equity of 181.52%.

CASI Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ CASI opened at $2.16 on Tuesday. The firm has a market cap of $33.46 million, a price-to-earnings ratio of -0.97 and a beta of 0.41. CASI Pharmaceuticals has a 1 year low of $2.04 and a 1 year high of $7.67. The company has a debt-to-equity ratio of 1.38, a quick ratio of 2.32 and a current ratio of 3.20. The stock’s 50-day simple moving average is $2.38 and its 200-day simple moving average is $3.82.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of CASI Pharmaceuticals in a research report on Thursday, March 27th. They set a “hold” rating on the stock.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.